Literature DB >> 3027841

Itraconazole in the treatment of vaginal candidosis and the effect of treatment of the sexual partner.

J J Calderón-Márquez.   

Abstract

The efficacy of itraconazole in the treatment of vaginal candidosis and the effect of treatment of the sexual partner were evaluated. Women received 100 mg of itraconazole daily for five days. The sexual partners of one-half of the women were treated with the same dosage of itraconazole; the other men received placebo. Study design was double blind. Sexual relations were discontinued during treatment. On day 0 and day 30 after initiation of treatment, laboratory values were determined. At 30 days, 14% of the women whose sexual partners had received placebo and none of those whose sexual partners had received itraconazole had relapsed. These differences, however, were not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3027841     DOI: 10.1093/clinids/9.supplement_1.s143

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  4 in total

Review 1.  Candidiasis (vulvovaginal).

Authors:  Des Spence
Journal:  BMJ Clin Evid       Date:  2010-01-05

Review 2.  [Mycotic infections of the anogenital region].

Authors:  P Mayser; W Hort; S Pflieger-Bruss
Journal:  Hautarzt       Date:  2005-06       Impact factor: 0.751

Review 3.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

4.  Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: 2. Factors that may have influenced the marked changes in sales volumes during the 1990s.

Authors:  Per-Anders Mårdh; Jolanta Wågström; Maria Landgren; Jan Holmén
Journal:  Infect Dis Obstet Gynecol       Date:  2004-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.